Burden of illness of follicular lymphoma and marginal zone lymphoma

Monga, Neerav; Nastoupil, Loretta J.; Garside, Jamie; Quigley, Joan; Hudson, M.; O′Donovan, Peter; Parisi, Lori; Tapprich, Christoph; Thiéblemont, Catherine

doi:10.1007/s00277-018-3501-8

Cited by 20 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[5][6][7] Overall, intermittent treatment, the need for surveillance, and the morbidity of therapy have a psychological, physical, and financial burden. 8 First-line treatment options for advanced MZL include anti-CD20 antibody monotherapy, chemotherapy, and combination chemoimmunotherapy. 3,4 Most patients will experience relapse after first-line therapy, but until recently the only treatment option for patients with relapsed disease was re-treatment with the same agents.…”

Section: Introductionmentioning

confidence: 99%

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg/d in 63 patients with relapsed/refractory MZL treated with prior rituximab (RTX) or rituximab-based chemoimmunotherapy (RTX-CIT). We report the final analysis of PCYC-1121 with median follow-up of 33.1 months (range: 1.4-44.6). Overall response rate (ORR) was 58%; median duration of response (DOR) was 27.6 months (95% confidence interval [CI]: 12.1 to not estimable [NE]); median progression-free survival (PFS) was 15.7 months (95% CI: 12.2-30.4); and median overall survival (OS) was not reached (95% CI: NE to NE). Patients with prior RTX treatment had better outcomes (ORR: 81%; median DOR: not reached [95% CI: 12.2 to NE]; median PFS: 30.4 months [95% CI: 22.1 to NE]; median OS: not reached [95% CI: 30.3 to NE]) vs those with prior RTX-CIT treatment (ORR: 51%; DOR: 12.4 months [95% CI: 2.8 to NE]; PFS: 13.8 months [95% CI: 8.3-22.5]; OS: not reached [95% CI: NE to NE]). ORRs were 63%, 47%, and 62% for extranodal, nodal, and splenic subtypes, respectively. With up to 45 months of ibrutinib treatment, the safety profile remained consistent with prior reports. The most common grade ≥3 event was anemia (16%). Exploratory biomarker analysis showed NF-κB pathway gene mutations correlated with outcomes. Final analysis of PCYC-1121 demonstrated long-term safety and efficacy of ibrutinib in patients with relapsed/refractory MZL, regardless of prior treatment or MZL subtype. This trial was registered at www.clinicaltrials.gov as #NCT01980628.

show abstract

Section: Introductionmentioning

confidence: 99%

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“… 1 – 4 In the United States, FL has an estimated incidence of 3 to 4 per 100 000 people and accounts for approximately 35% of NHLs. 1 , 5 , 6 In the United States, the estimated number of new cases in 2016 was 13 960. 5 Recent evidence indicates that about 30% to 50% of patients will relapse within 5 years of initial diagnosis.…”

Section: Introductionmentioning

confidence: 99%

“…A recent study showed that the annual costs for patients with FL who have progressive disease were about 3.5-fold higher than those with nonprogressive disease. 6 Furthermore, patients with advanced-stage disease often have higher mortality rates. 6 For example, a study by Mounier et al found that patients with stage I/II FL had a 21% mortality rate compared with 28% for patients with stage III/IV disease.…”

Section: Introductionmentioning

confidence: 99%

“… 6 Furthermore, patients with advanced-stage disease often have higher mortality rates. 6 For example, a study by Mounier et al found that patients with stage I/II FL had a 21% mortality rate compared with 28% for patients with stage III/IV disease. 24 Beyond the financial and clinical burdens of FL, 6 patients with active relapsed disease tend to have poorer scores than their newly diagnosed counterparts in quality of life (QoL), anxiety, depression, and work productivity.…”

Section: Introductionmentioning

confidence: 99%

“… 6 For example, a study by Mounier et al found that patients with stage I/II FL had a 21% mortality rate compared with 28% for patients with stage III/IV disease. 24 Beyond the financial and clinical burdens of FL, 6 patients with active relapsed disease tend to have poorer scores than their newly diagnosed counterparts in quality of life (QoL), anxiety, depression, and work productivity. 6 , 25 , 26 Due to the lack of curative options and the significant financial and QoL burden associated with relapsed disease, new treatment strategies for FL are needed.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

reatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma

Fowler

Chen

Lim

et al. 2023

JHEOR

View full text Add to dashboard Cite

Background: Few studies have estimated the real-world economic burden such as all-cause and follicular lymphoma-related costs and health care resource utilization (HCRU) in patients with follicular lymphoma (FL). Objectives: This study evaluated outcomes in patients who were newly initiated with FL indicated regimens by line of therapy with real-world data. Methods: A retrospective study was conducted among patients with FL from MarketScan® databases between January 1, 2010 and December 31, 2013. Patients were selected if they were ≥18 years old when initiated on a FL indicated therapy, had at least 1 FL-related diagnosis, ≥1 FL commonly prescribed systemic anti-cancer therapy after diagnosis, and did not use any FL indicated regimen in the 24 months prior to the first agent. These patients were followed up at least 48 months and the outcomes, including the distribution of regimens by line of therapy, the treatment duration by line of therapy, all-cause and FL-related costs, and HCRU by line of therapy were evaluated. Results: This study identified 598 patients who initiated FL indicated treatment. The average follow-up time was approximately 5.7 years. Of these patients, 50.2% (n=300) were female, with a mean age of 60.7 years (SD=13.1 years) when initiating their treatment with FL indicated regimens. Overall, 598 (100%) patients received first-line therapy, 180 (43.6%) received second-line therapy, 51 received third-line therapy, 21 received fourth-line therapy, and 10 received fifth-line therapy. Duration of treatment by each line of therapy was 370 days, 392 days, 162 days, 148 days, and 88 days, respectively. The most common first-line regimens received by patients were rituximab (n=201, 33.6%), R-CHOP (combination of rituximab, cyclophosphamide, doxorubicin hydrochloride [hydroxydaunomycin]; n=143, 24.0%), BR (combination of bendamustine and rituximab; n=143, 24.0%), and R-CVP (combination of rituximab, cyclophosphamide, vincristine, and prednisone; n=71, 11.9%). The most common second-line treatment regimens were (N=180): rituximab (n=78, 43.3%) and BR (n=41, 22.8%). Annualized all-cause health care costs per patient ranged from US$97 141 (SD: US$144 730) for first-line to US$424 758 (SD: US$715 028) for fifth-line therapy. Conclusions: The primary regimens used across treatment lines conform to those recommended by the National Comprehensive Cancer Network clinical practice guidelines. The economic burden for patients with FL is high and grows with subsequent lines of therapy.

show abstract

Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study

Nerich

Guyeux

Henry-Amar³

et al. 2021

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUND:No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors. METHODS: Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs. RESULTS: In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs. CONCLUSIONS: The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design personcentered health care pathways.

show abstract

Burden of illness of follicular lymphoma and marginal zone lymphoma

Cited by 20 publications

References 43 publications

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

reatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma

Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study

Contact Info

Product

Resources

About